LNTH

Lantheus Holdings Inc. (LNTH) | Rumor.io

Lantheus Holdings

LNTH

Attention (50-day avg)0%

Attention rank (50-day avg)#3,062

Bullish sentiment (50-day avg)97%

Price to earnings ratio23.9

Market capitalization6.5B

Earnings per share4.18

Dividend yield (TTM)—

Revenue (annual)1.5B

Net income (annual)233.6M

Social

What share of all stock conversation is about LNTH?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% 0	0% 0

Aug 3

Lantheus Holdings, Inc. (LNTH) has signed a definitive agreement to merge with a unit of Curium US Holdings in a transaction valued at up to $8 billion.
The buyer will pay $102 per Lantheus share in cash at closing and up to $12 per share in future milestone-based cash payments through 2030.
The deal represents a premium of 21% to Lantheus shares before news of a deal broke, and the acquisition is expected to be supportive for Telix Pharmaceuticals (TLX).

Generated by AI

Sentiment

Of the messages about LNTH that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	100% +3.57	85.29% -3.1
Bearish	—	—	0% -3.57	14.71% +3.1

Bullish· Aug 6

The company's recent buyback authorization and strong cash position could lead to a significant reduction in share count, potentially driving the stock price higher.
The stock has a history of strong bounces from the $48-$50 zone, suggesting that it could rebound to over $100+ a share from this level.
The stock is heavily institutionally held, with over 95% of outstanding shares owned by institutions, which could lead to controlled price movements and potentially drive the stock price higher.

Bearish· Aug 6

The company's Pylarify growth has been finished due to competition, and it may take until the Alzheimer diagnostic product comes to market for the stock to recover.
The recent earnings miss, with a 12.78% YoY decline in adj. EPS and a 4.07% YoY decline in revenue, has led to a significant share price drop.
The company's stock price has been crushed despite a relatively minor earnings miss, suggesting that the market is overreacting and that the stock may be undervalued at current levels.

Generated by AI

Topics

Of the messages about LNTH that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	—	14.29%	58.41%
Technical Analysis	—	—	0%	18.34%
Analysts	—	—	85.71%	17.03%
Earnings	—	—	0%	4.15%
Controversies	—	—	0%	0.11%
Macro	—	—	0%	1.97%

Earnings· May 4

$LNTH reported Q1 earnings with revenues of $300.8M (up 44% YoY) and non-GAAP EPS of $1.47 (up 51.5% YoY).
The company guided Q2 revenues of $300-310M and EPS of $1.25-1.33, above consensus estimates.
$LNTH updated FY23 guidance to $5.45-5.70 EPS and revenue guidance to $1.23-1.27 billion, reflecting a 10% increase in revenue guidance.

Announcements· Aug 3

Curium US Holdings will acquire Lantheus Holdings, Inc. (LNTH) for up to $8 billion, with shareholders receiving $102.50 per share in cash at closing and up to $12 per share in non-transferable Contingent Value Rights (CVRs).
The deal represents a premium of 21% to Lantheus shares before news of the acquisition broke, and the total consideration of up to $114.50 per share is a significant premium to Lantheus' unaffected closing price.
The acquisition is expected to be financed through a combination of debt and equity, and is subject to satisfaction of customary closing conditions, including receipt of Lantheus shareholder approval and required regulatory approvals, with a closing expected in the first half of 2027.

Generated by AI

Community

Of the messages about LNTH, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	—	11.11%	49.76%
Newcomers	—	—	88.89%	50.24%

Regulars· Oct 3

A Jefferies analyst has set a price target of $110.00 for LNTH.
LNTH's willingness to take calculated risks and do deals is being contrasted with INMD's conservative management approach.
LNTH has seen notable trading activity, closing up 10.35% and trading 213% above average volume.

Newcomers· Oct 3

New investors are focusing on the rapid price increase of Lantheus Holdings ($LNTH) by 10.35% in a short period, with some attributing it to increased activity in the healthcare sector by large investors (whales).
Some newcomers are using $LNTH as part of a momentum trade, buying the stock along with others that have seen significant gains in recent days.
A newcomer is taking partial profit and de-risking a pair trade involving $LNTH and another stock ($LLY), highlighting the potential for shorting or hedging against $LNTH.

Generated by AI

FDA approval for BRAVNETSA puts Lantheus Holdings (LNTH) in focus Lantheus Holdings (LNTH) drew fresh attention after the FDA granted final approval for BRAVNETSA, a radiopharmaceutical considered bioequivalent and therapeutically equivalent to LUTATHERA for adult GEP NET patients. The BRAVNETSA approval lands at a time when Lantheus Holdings has seen short term share price pressure, with the stock down over the past three months. Yet its year to date share price return of 48.27% and 1 year...

3d agoYahoo Finance

Strong Earnings, FDA Approval, and Takeover Interest Drive Lantheus Holdings’ (LNTH) Rally

Polaris Capital Management, an investment management company, released its second-quarter 2026 investor letter for “Global Equity Strategy”. The letter can be downloaded here. Global markets delivered strong gains during the quarter, supported by an AI-driven earnings rally despite elevated interest rates, inflation concerns, and geopolitical uncertainty. Polaris Global Equity Composite (net of fees) returned 13.26% […]

6d agofinance.yahoo.com

FDA approves Lantheus’ BRAVNETSA for neuroendocrine tumors

7d agoInvesting.com

Lantheus Says Curium Resubmits Antitrust Filing for Merger

Lantheus Holdings (LNTH) said Monday that Curium resubmitted its pre-merger notification, beginning

8d agoYahoo Finance

Lantheus alpha therapy, CATX director, sells $131k in stock

25d agoInvesting.com

Also Discussed

Investors talking about LNTH also mention

#	Name	Attention
1	SWAV - ShockWave Medical, Inc.	——
2	Harmony Biosciences Holdings, Inc.HRMY	0%new
3	Amphastar Pharmaceuticals, Inc.AMPH	0%new
4	Axcelis Technologies Inc.ACLS	0%0
5	Onto Innovation Inc.ONTO	0%-0.02
6	Hudson Technologies, Inc.HDSN	0.01%new
7	Constellium SE Class A Ordinary SharesCSTM	0%new
8	GE HealthCare Technologies Inc.GEHC	0%0
9	Evolent Health IncEVH	0%0
10	Alkermes plcALKS	0%0

Lantheus Holdings Inc.

Healthcare
Drug Manufacturers - Specialty & Generic

Lantheus Holdings Inc. is a radiopharmaceutical-focused healthcare company that develops, manufactures, and commercializes diagnostic and therapeutic products used to help clinicians detect, localize, and monitor disease. Its portfolio centers on precision diagnostics and nuclear medicine solutions for oncology, cardiology, and neurology, with products designed to support imaging-based diagnosis and patient management across hospitals, clinics, and other healthcare settings. The company’s current business also includes radiotherapeutics and strategic partnerships that complement its core imaging franchise. Lantheus Holdings Inc. serves a global medical market where advanced diagnostic agents play an important role in guiding treatment decisions and improving disease visibility in clinical practice. Headquartered in Bedford, Massachusetts, Lantheus Holdings Inc. operates as a specialized provider in molecular imaging and related healthcare technologies.

Website

Location

201 Burlington Road

Bedford, MA, 01730

United States

Social

What share of all stock conversation is about LNTH?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% 0	0% 0

Aug 3

Lantheus Holdings, Inc. (LNTH) has signed a definitive agreement to merge with a unit of Curium US Holdings in a transaction valued at up to $8 billion.
The buyer will pay $102 per Lantheus share in cash at closing and up to $12 per share in future milestone-based cash payments through 2030.
The deal represents a premium of 21% to Lantheus shares before news of a deal broke, and the acquisition is expected to be supportive for Telix Pharmaceuticals (TLX).

Generated by AI

Sentiment

Of the messages about LNTH that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	100% +3.57	85.29% -3.1
Bearish	—	—	0% -3.57	14.71% +3.1

Bullish· Aug 6

The company's recent buyback authorization and strong cash position could lead to a significant reduction in share count, potentially driving the stock price higher.
The stock has a history of strong bounces from the $48-$50 zone, suggesting that it could rebound to over $100+ a share from this level.
The stock is heavily institutionally held, with over 95% of outstanding shares owned by institutions, which could lead to controlled price movements and potentially drive the stock price higher.

Bearish· Aug 6

The company's Pylarify growth has been finished due to competition, and it may take until the Alzheimer diagnostic product comes to market for the stock to recover.
The recent earnings miss, with a 12.78% YoY decline in adj. EPS and a 4.07% YoY decline in revenue, has led to a significant share price drop.
The company's stock price has been crushed despite a relatively minor earnings miss, suggesting that the market is overreacting and that the stock may be undervalued at current levels.

Generated by AI

Topics

Of the messages about LNTH that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	—	14.29%	58.41%
Technical Analysis	—	—	0%	18.34%
Analysts	—	—	85.71%	17.03%
Earnings	—	—	0%	4.15%
Controversies	—	—	0%	0.11%
Macro	—	—	0%	1.97%

Earnings· May 4

$LNTH reported Q1 earnings with revenues of $300.8M (up 44% YoY) and non-GAAP EPS of $1.47 (up 51.5% YoY).
The company guided Q2 revenues of $300-310M and EPS of $1.25-1.33, above consensus estimates.
$LNTH updated FY23 guidance to $5.45-5.70 EPS and revenue guidance to $1.23-1.27 billion, reflecting a 10% increase in revenue guidance.

Announcements· Aug 3

Curium US Holdings will acquire Lantheus Holdings, Inc. (LNTH) for up to $8 billion, with shareholders receiving $102.50 per share in cash at closing and up to $12 per share in non-transferable Contingent Value Rights (CVRs).
The deal represents a premium of 21% to Lantheus shares before news of the acquisition broke, and the total consideration of up to $114.50 per share is a significant premium to Lantheus' unaffected closing price.
The acquisition is expected to be financed through a combination of debt and equity, and is subject to satisfaction of customary closing conditions, including receipt of Lantheus shareholder approval and required regulatory approvals, with a closing expected in the first half of 2027.

Generated by AI

Community

Of the messages about LNTH, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	—	11.11%	49.76%
Newcomers	—	—	88.89%	50.24%

Regulars· Oct 3

A Jefferies analyst has set a price target of $110.00 for LNTH.
LNTH's willingness to take calculated risks and do deals is being contrasted with INMD's conservative management approach.
LNTH has seen notable trading activity, closing up 10.35% and trading 213% above average volume.

Newcomers· Oct 3

New investors are focusing on the rapid price increase of Lantheus Holdings ($LNTH) by 10.35% in a short period, with some attributing it to increased activity in the healthcare sector by large investors (whales).
Some newcomers are using $LNTH as part of a momentum trade, buying the stock along with others that have seen significant gains in recent days.
A newcomer is taking partial profit and de-risking a pair trade involving $LNTH and another stock ($LLY), highlighting the potential for shorting or hedging against $LNTH.

Generated by AI

Lantheus Holdings

Social

Aug 3

Bullish· Aug 6

Bearish· Aug 6

Earnings· May 4

Announcements· Aug 3

Regulars· Oct 3

Newcomers· Oct 3

Lantheus doses first patient in prostate cancer imaging trial

Lantheus Holdings (LNTH) Could Be 7% Undervalued On BRAVNETSA Approval

Strong Earnings, FDA Approval, and Takeover Interest Drive Lantheus Holdings’ (LNTH) Rally

FDA approves Lantheus’ BRAVNETSA for neuroendocrine tumors

Lantheus Says Curium Resubmits Antitrust Filing for Merger

Lantheus alpha therapy, CATX director, sells $131k in stock

Also Discussed

Lantheus Holdings Inc.

Company Information

Location

Lantheus doses first patient in prostate cancer imaging trial

Lantheus Holdings (LNTH) Could Be 7% Undervalued On BRAVNETSA Approval

Strong Earnings, FDA Approval, and Takeover Interest Drive Lantheus Holdings’ (LNTH) Rally

FDA approves Lantheus’ BRAVNETSA for neuroendocrine tumors

Lantheus Says Curium Resubmits Antitrust Filing for Merger

Lantheus alpha therapy, CATX director, sells $131k in stock

Also Discussed

Social

Aug 3

Bullish· Aug 6

Bearish· Aug 6

Earnings· May 4

Announcements· Aug 3

Regulars· Oct 3

Newcomers· Oct 3